KemPharm, Inc. (KMPH)
| Market Cap | 372.50M |
| Revenue (ttm) | 23.32M |
| Net Income (ttm) | -54.75M |
| Shares Out | 19.15M |
| EPS (ttm) | -6.83 |
| PE Ratio | n/a |
| Forward PE | 28.90 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $10.31 |
| Previous Close | $10.99 |
| Change ($) | -0.68 |
| Change (%) | -6.19% |
| Day's Open | 11.09 |
| Day's Range | 10.26 - 11.25 |
| Day's Volume | 739,397 |
| 52-Week Range | 5.08 - 18.15 |
CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced t...
Investors reacted negatively to the company's warrant exchange.
CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced i...
CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
KemPharm Inc. (NASDAQ:KMPH) shares moved higher Thursday after it was announced the company is being added to the Russell 3000 and Russell 2000 indexes based on the index provider's annual reconstitutio...
CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today i...
CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
SDX is KemPharm's proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™
Corporate and Regulatory Highlights
KP879, KemPharm's Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET
Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX
KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M
KemPharm Inc (NASDAQ: KMPH) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to d...
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales
KemPharm has a new ADHD drug, but after a recent short-squeeze KMPH stock is likely to fall without further financing. The post KemPharm Stock Is Too Good to Be True After Its Recent Run-up appeared fir...
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME). The post KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Sque...
Corporate and Regulatory Highlights:
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET
CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...
KemPharma (KMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
What a day. We saw the morning start with a new iteration of the Reddit stocks rally, and the afternoon close with new fears about digital ad companies.
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...
KemPharm's prodrug development platform got a huge boost from the FDA's new drug application nod for an ADHD treatment. The post KMPH Stock: The Big News That Has KemPharm Soaring Today appeared first o...
The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (AD...
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
Financial Restructuring and Nasdaq Re-Listing Process Completed
Combination of Oral and Poster Presentations Scheduled for January 15, 2021
CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021
CELEBRATION, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...
CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it...
CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET
IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline , Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH)
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET
Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020, 8:00 a.m. ET
CELEBRATION, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced th...
New agreement provides additional revenue potentially through Q1 2022
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
CELEBRATION, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietar...
Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment
Presentations to Highlight Corporate, Regulatory and Pipeline Advancements Presentations to Highlight Corporate, Regulatory and Pipeline Advancements
CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced ...
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesd...
About KMPH
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CN... [Read more...]
| Industry Biotechnology | IPO Date Apr 16, 2015 |
| CEO Travis Mickle | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol KMPH |
Financial Performance
In 2020, KemPharm's revenue was $13.29 million, an increase of 3.50% compared to the previous year's $12.84 million. Losses were -$12.76 million, -47.97% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for KemPharm is 19.00, which is an increase of 84.29% from the latest price.